company background image
4GB logo

Gossamer Bio DB:4GB Stock Report

Last Price

€0.73

Market Cap

€182.4m

7D

-7.9%

1Y

-7.6%

Updated

23 Dec, 2024

Data

Company Financials +

4GB Stock Overview

A clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. More details

4GB fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Gossamer Bio, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Gossamer Bio
Historical stock prices
Current Share PriceUS$0.73
52 Week HighUS$1.46
52 Week LowUS$0.45
Beta1.89
1 Month Change17.91%
3 Month Change-16.40%
1 Year Change-7.63%
3 Year Change-92.73%
5 Year Change-94.64%
Change since IPO-95.55%

Recent News & Updates

Recent updates

Shareholder Returns

4GBDE BiotechsDE Market
7D-7.9%-3.5%-2.0%
1Y-7.6%-14.7%6.9%

Return vs Industry: 4GB exceeded the German Biotechs industry which returned -14.7% over the past year.

Return vs Market: 4GB underperformed the German Market which returned 6.9% over the past year.

Price Volatility

Is 4GB's price volatile compared to industry and market?
4GB volatility
4GB Average Weekly Movement9.1%
Biotechs Industry Average Movement6.8%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 4GB's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 4GB's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2015135Faheem Hasnainwww.gossamerbio.com

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds.

Gossamer Bio, Inc. Fundamentals Summary

How do Gossamer Bio's earnings and revenue compare to its market cap?
4GB fundamental statistics
Market cap€182.43m
Earnings (TTM)-€68.67m
Revenue (TTM)€100.94m

1.8x

P/S Ratio

-2.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4GB income statement (TTM)
RevenueUS$105.32m
Cost of RevenueUS$0
Gross ProfitUS$105.32m
Other ExpensesUS$176.97m
Earnings-US$71.65m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.32
Gross Margin100.00%
Net Profit Margin-68.03%
Debt/Equity Ratio364.4%

How did 4GB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 15:34
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Gossamer Bio, Inc. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Carter GouldBarclays
Zhilin LongBerenberg
Patrick TrucchioBerenberg